{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antiretroviral+drugs&page=13", "query": { "intervention": "Antiretroviral drugs", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 534, "total_pages": 54, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antiretroviral+drugs&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antiretroviral+drugs&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T01:24:08.202Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04302896", "title": "Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Medication Adherence", "HIV" ], "interventions": [ { "name": "dolutegravir oral tablet 50mg", "type": "DRUG" }, { "name": "emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg", "type": "DRUG" }, { "name": "tenofovir disoproxil fumarate oral tablet 300mg", "type": "DRUG" }, { "name": "lamivudine oral tablet 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhonda Brand", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-08-31", "completion_date": "2021-09-30", "has_results": false, "last_update_posted_date": "2022-03-03", "last_synced_at": "2026-10-14T01:24:08.202Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04302896" }, { "nct_id": "NCT00071890", "title": "Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Interleukin 2", "type": "DRUG" }, { "name": "HAART", "type": "DRUG" }, { "name": "Treatment interruption", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2003-10", "completion_date": "2007-12", "has_results": true, "last_update_posted_date": "2010-10-05", "last_synced_at": "2026-10-14T01:24:08.202Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00071890" }, { "nct_id": "NCT00775606", "title": "Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acquired Immune Deficiency Syndrome" ], "interventions": [ { "name": "Lopinavir 400 mg/ritonavir 100 mg", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 15, "start_date": "2008-10", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-10-14T01:24:08.202Z", "location_count": 4, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00775606" }, { "nct_id": "NCT01285050", "title": "Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infection", "Hepatitis C" ], "interventions": [ { "name": "Antiretroviral therapy (ART)", "type": "DRUG" }, { "name": "raltegravir", "type": "DRUG" }, { "name": "Emtricitabine and tenofovir disoproxil fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 20, "start_date": "2011-01", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-10-14T01:24:08.202Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01285050" }, { "nct_id": "NCT02704208", "title": "A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Thrive With Me Control", "type": "BEHAVIORAL" }, { "name": "Thrive With Me Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 410, "start_date": "2016-10-01", "completion_date": "2022-05-31", "has_results": true, "last_update_posted_date": "2023-06-07", "last_synced_at": "2026-10-14T01:24:08.202Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02704208" }, { "nct_id": "NCT00006208", "title": "A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Efavirenz", "type": "DRUG" }, { "name": "Emtricitabine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Triangle Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-14T01:24:08.202Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Berkeley, California • Concord, California + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Berkeley", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006208" }, { "nct_id": "NCT00054717", "title": "Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Tipranavir", "type": "DRUG" }, { "name": "Ritonavir(r)", "type": "DRUG" }, { "name": "Comparator Protease Inhibitor (CPI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2003-01", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-07-02", "last_synced_at": "2026-10-14T01:24:08.202Z", "location_count": 96, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 67 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054717" }, { "nct_id": "NCT00001108", "title": "A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Ritonavir", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" }, { "name": "Nevirapine", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "22 Years", "sex": "ALL", "summary": "4 Years to 22 Years" }, "enrollment_count": 6, "start_date": null, "completion_date": "2000-06", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-14T01:24:08.202Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • Miami, Florida + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001108" }, { "nct_id": "NCT00002450", "title": "Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Tenofovir disoproxil fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 600, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-14T01:24:08.202Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002450" }, { "nct_id": "NCT01164605", "title": "Pilot Study of Raltegravir Lipodystrophy IISP", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Southern California Institute for Research and Education", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "2010-10", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2012-05-18", "last_synced_at": "2026-10-14T01:24:08.202Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01164605" } ] }